GlassScriptPhysician profile
Larry Bergere
NPI 1609966613
$3,317.47
in general payments reported to CMS, 2019-2025
34 companies · $644 in 2025
The $644 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $409 · 2023: $1,263 · 2024: $1,001 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,908.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $522.57 | 2022-2024 | Mounjaro, Trulicity, Zepbound |
| Novo Nordisk INC | $426.21 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $272.38 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.69 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $167.52 | 2023-2025 | Freestyle Libre 3 |
| Abbvie INC. | $167.29 | 2022-2024 | Ubrelvy, Vraylar, Qulipta |
| Sanofi-Aventis U.S. LLC | $119.58 | 2024-2025 | |
| Pfizer INC. | $115.90 | 2022-2024 | |
| Dexcom, INC. | $111.70 | 2022-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $110.35 | 2022-2025 | |
| Glaxosmithkline, LLC. | $101.97 | 2023-2025 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $97.69 | 2024-2025 | |
| Corcept Therapeutics | $95.61 | 2025 | Korlym |
| Exact Sciences Corporation | $81.66 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Insulet Corporation | $74.01 | 2023-2025 | Omnipod |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $73.17 | 2022-2023 | Linzess |
| Xeris Pharmaceuticals, INC. | $68.73 | 2023 | Gvoke Hypopen |
| Boston Scientific Corporation | $53.21 | 2024 | Varithena Administration Pack |
| Amgen INC. | $45.20 | 2024-2025 | Evenity, Prolia, Otezla |
| Corium, LLC | $39.68 | 2023 | Adlarity |
| Medtronic, INC. | $37.22 | 2025 | Interstim |
| Janssen Pharmaceuticals, INC | $35.40 | 2023 | Xarelto |
| Verona Pharma, INC. | $33.65 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $33.57 | 2023 | Steglatro, Belsomra |
| Hologic Sales and Service, LLC | $21.76 | 2024 | Aptima |
| Astellas Pharma US INC | $21.18 | 2023 | Veozah |
| Amphastar Pharmaceuticals, INC. | $20.70 | 2024 | |
| Seqirus USA INC | $17.04 | 2022 | |
| Mylan Specialty L.P. | $17.00 | 2024 | Yupelri |
| Idorsia Pharmaceuticals US INC | $15.05 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.61 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.35 | 2024 | Rexulti |
| Horizon Therapeutics Plc | $13.94 | 2023 | Krystexxa |
| Linus Health, INC. | $13.88 | 2024 | Core Cognitive Evaluation |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Bergere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.